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Abstract   
Objectives: To examine incidence of treatment changes due to abnormal blood-test results 
and, to explore rates of treatment changes due to liver, kidney and haematological blood-
test abnormalities  in autoimmune rheumatic diseases (AIRD) treated with low-dose 
methotrexate or leflunomide. 
Methods: Data for people with AIRDs prescribed methotrexate or leflunomide were 
extracted from the Clinical Practice Research Datalink. Participants were followed-up from 
first prescription of methotrexate or leflunomide in primary-care. Primary outcome of interest 
was drug discontinuation, defined as a prescription gap of ≥90 days following an abnormal 
(or severely abnormal) blood-test result. Dose reduction was examined between 
consecutive prescriptions.  Incidence rates per 1,000 person-years were calculated.  
Results: 15,670 and 2,689 participants contributing 46,571 and 4,558 person-years follow-
up were included in methotrexate and leflunomide cohorts respectively. The incidence of 
methotrexate and leflunomide discontinuation with abnormal (severely abnormal) blood-test 
was 42.24(6.16) and 106.53(9.42)/1,000 person-years in year-1, and 22.44(2.84) and 
31.69(4.40)/1,000 person-years respectively thereafter. The cumulative incidence of 
methotrexate and leflunomide discontinuation with abnormal (severely abnormal) blood-
tests was 1 in 24(1 in 169), 1 in 9(1 in 106) at 1-year; and 1 in 45(1 in 352), 1 in 32(1 in 227) 
per-year respectively thereafter. Raised liver enzymes were the commonest abnormality 
associated with drug discontinuation. Methotrexate and leflunomide dose reduction 
incidence were comparable in year-1, however, thereafter methotrexate dose was reduced 
more often than leflunomide (16.60(95% CI; 13.05-21.13) vs. 8.10(95% CI; 4.97-
13.20)/1,000 person-years). 














after year-1 of treatment, however, discontinuations for severely abnormal results were 
uncommon. 
Key words  





Key messages  
• Treatment discontinuation and dose reductions were more common in the first year 
of treatment and occurred at a stable but lower rate thereafter.  
• Severely abnormal blood-test results were uncommonly associated with 
methotrexate and leflunomide discontinuations. 

















Autoimmune rheumatic diseases (AIRDs) affect >1% adults and are treated with disease 
modifying anti-rheumatic drugs (DMARDs) (1-5). These drugs can cause cytopenia, raised 
liver enzymes, and acute kidney injury (AKI) and, fortnightly to monthly monitoring blood-
tests are recommended when initiating treatment with less frequent testing thereafter (6). 
In the UK, DMARDs are initiated in a rheumatology clinic with prescriptions dispensed 
from the hospital and fortnightly blood monitoring overseen by the rheumatology 
team. Once an effective, tolerated and stable dose is reached, the responsibility for 
prescribing and arranging 2-3 monthly blood-tests is handed to the GP under shared-
care policy supported by the British Society for Rheumatology (BSR) and Royal 
College of General Practitioners (6). The rheumatology team is contacted if there are 
side-effects, including blood-test abnormalities, and oversee treatment changes. 
Monitoring blood-tests are discontinued after two years for sulfasalazine whilst long-term 
testing is continued for  low-dose methotrexate and leflunomide (6, 7). Whether such long-
term testing influences the decision to discontinue treatment is not known because most 
clinical trials are shorter than one year, and many observational studies report cumulative 
toxicity including outcomes from the treatment initiation phase during which reversible drug-
induced target organ injury is common (8-10). However, evidence from a large 2-year 
clinical trial suggests that DMARD discontinuation due to target organ damage becomes 
less common with increasing duration of treatment (10). With growing use of DMARDs and 
the corresponding increased burden and cost of testing, it is important to evaluate the 
benefit from regular monitoring blood-tests for long-term low-dose methotrexate or 
leflunomide treatment (11). Thus, the objectives of this study were to examine the incidence 
of drug discontinuation and dose reduction with abnormal blood-test results in AIRDs 














examine whether the incidence of methotrexate discontinuation due to any abnormal blood-
test result, elevated liver enzymes, AKI or cytopenia differed in Rheumatoid Arthritis (RA) 
and psoriatic arthritis as there is evidence that psoriasis increases the risk of hepatotoxicity 
from methotrexate (12, 13).   
 
Methods  
Data source Data from Clinical Practice Research Datalink (CPRD) Gold was used. 
Incepted in 1987, CPRD-Gold is a longitudinal anonymized electronic database of 
health records from over 19 million participants in 927 GP practices across the UK and 
covers 4.52% of UK residents currently. CPRD participants are representative of the 
UK population in terms of age, sex, and ethnicity (14). CPRD includes information on 
demographic details, lifestyle factors (e.g. smoking, alcohol intake), diagnoses, results 
of investigations including blood tests and physical examination, and details of all GP 
prescriptions (14). Diagnostic and prescription data are recorded as Read codes, and 
product codes respectively. Blood-test results are stored as numeric values. 
Additionally, GPs may record abnormal blood-test results using Read codes. 
Approvals Independent Scientific Advisory Committee of the MHRA (Reference: 
19_275R).  
Study design Cohort study. Two separate cohorts were constructed comprising of 
participants prescribed methotrexate and leflunomide respectively.  
Study duration 1st January 2007 to 31st December 2019. The study began on 1st 
January 2007 as the BSR guidelines recommending aggressive treatment of RA and 
shared-care monitoring of DMARDs were published in 2006 (4, 15). 














• Diagnosed with either RA, systemic lupus erythematosus (SLE), psoriatic 
arthritis, reactive arthritis, ankylosing spondylitis, inflammatory bowel disease 
associated arthritis, giant cell arteritis, polymyalgia rheumatica, or connective 
tissue diseases (CTDs) at age ≥18 years, within the study period. 
• ≥1 GP prescription of methotrexate (oral or subcutaneous) or leflunomide after 
the first record of AIRD diagnosis in CPRD.  
• Continuous registration for ≥1 year before the first AIRD diagnosis date in a GP 
practice contributing research quality data to CPRD..  
The latter two criteria prevents prevalent AIRD cases on long-term DMARDs that 
have recently changed GP surgeries from entering the cohort as incident cases.  
Exclusion criteria: Chronic liver disease (autoimmune hepatitis, primary sclerosing 
cholangitis, hepatitis B or C, cirrhosis); haematological malignancies (lymphoma, 
leukaemia); myelodysplasia; haemolytic anaemia, neutropenia, idiopathic 
thrombocytopenic purpura; or chronic kidney disease (CKD) stage >=4 prior to cohort 
entry. 
Cohort entry: First shared-care GP prescription of methotrexate or leflunomide 
respectively.  
Cohort exit: The earliest of date of outcome, death, transfer out of the GP practice, last 
data collection from the GP practice, or 31/12/2019. For the dose reduction analysis, 
follow-up was censored on the first prescription date at which dose data were missing. 
Outcomes:  
[1] Drug discontinuation with abnormal blood-test result: Prescription gap of >=90 days 
following an abnormal blood-test result or Read code indicating abnormal blood-test 
result within +/-60 days of the date of last prescription. The thresholds for abnormal 














platelets <140x109/L, ALT/AST >100 IU/L(6); and kidney function decline defined as 
either CKD progression based on Read codes entered by the GP using KDIGO CKD 
guidelines (16), or a creatinine increase of >26 μmol/L, the threshold for consideration of 
AKI (17). 
[2] Drug discontinuation with severe abnormal blood-test result: Prescription gap of 
≥90 days, with severely abnormal monitoring blood-test result within +/-60 days of the 
date of last prescription. Severe blood-test abnormalities were defined as: WBCs 
<2.5x109/L, neutrophils <1.0x109/L, platelets <50x109/L, ALT or AST >200 IU/L or 
serum creatinine >2 times the previous value. These thresholds were selected as they 
reflect grade-3 cytopenia according to Common Terminology Criteria for Adverse 
Events, stage 2 acute kidney injury according to the KDIGO guidelines, and meet the 
criteria for drug induced liver injury with ALT or AST >5-times upper limit of normal 
(17-19). 
[3] Dose reduction with abnormal, and severely abnormal blood-test result: Dose 
reduction between two consecutive prescriptions. 
[4] Drug discontinuation (any reason): Gap of ≥90 days between the last prescription 
date and the earliest of date of death, transfer out of the GP practice, last data 
collection from GP practice, or 31/12/2019.   
Data management: Read code and product code lists were developed to ascertain 
AIRDs, inclusion and exclusion criteria, prescriptions, and outcomes (Available on 
request).   
Outcome validation:  A random sample (40%) of methotrexate discontinuations with a 
blood-test abnormality was drawn. Data for all consultations within +/- 60 days of the 
abnormal blood-test result was extracted. AA (Consultant Rheumatologist trained in 














administrative codes e.g. reminder letter sent, telephone appointment etc. All clinical 
experts in the study team (two rheumatologists, one nephrologist, one hepatologist, 
one gastroenterologist, one haematologist (CF) and one academic GP) reviewed the 
remaining Read codes. Each expert could vote in any condition if they felt that the 
condition, its treatment, or its complications could cause blood, liver, or kidney injury. 
The final list was reviewed by all clinicians and four Read codes were excluded as 
they were non-specific or could imply DMARD side effects if used alone (Table S 1).  
Statistical analyses Mean (standard deviation(SD)) and n(%) were used for descriptive 
purposes. The proportion of methotrexate discontinuations with blood test abnormality 
that could potentially be explained by an underlying illness was determined. Survival 
analysis was undertaken to calculate the incidence of outcomes (95% confidence 
intervals (CI)) per 1,000 person-years for entire follow-up period, first 12-months of 
follow-up, and the subsequent period. Incidence of drug discontinuation or dose 
reduction with individual blood-test abnormalities were calculated. Missing data on 
doses were not imputed as they were missing not at random and imputation could 
create spurious outcomes. Life tables were constructed to estimate the cumulative 
incidence at 1-year and 5-year follow-up. Cumulative hazards were plotted using 
Nelson-Aalen graphs.  
Sensitivity analysis: The incidence of methotrexate discontinuation for blood-test 
abnormalities was examined in a sensitivity analysis after excluding cases with SLE 
and other CTDs as these conditions can cause cytopenia. The incidence of 
methotrexate discontinuation with abnormal blood-test results was calculated 
separately for RA and psoriatic arthritis. Data management and analysis were 















Results Data for 24,871 and 3,897 participants with AIRDs prescribed methotrexate 
and leflunomide were ascertained. Of these, 15,670 and 2,689 participants 
contributing 46,571 and 4,558 person-years follow-up were included in the 
methotrexate and leflunomide cohorts, respectively (Figures S1-S2). The median 
(IQR) methotrexate and leflunomide dose at cohort entry was 10 (7.5-15) mg/week 
and 10 (10-20) mg/day respectively. 2.1% participants were prescribed both drugs at 
cohort entry or within the first six-months. The majority of participants in the 
methotrexate cohort had RA (65.8%), were female (64.6%) and their mean (SD) age 
was 57 (15) years. In the leflunomide cohort, 63.9% had RA, 67.3% were female and 
the mean (SD) age was 57 (13) years (Table 1). The median (IQR) follow-up in the 
methotrexate and leflunomide cohorts was 2.31 (0.82-4.92) and 1.03 (0.33-2.94) 
years, and there were 1,262 and 259 drug discontinuations due to abnormal 
monitoring blood test results respectively. Of these 95.6% and 95% were ascertained 
using values of blood-test results while the remainder were ascertained using Read 
codes. The 40% random sample of methotrexate discontinuations with blood-test 
abnormalities consisted of 505 cases and yielded 27 (5.35%) discontinuations that 
could potentially be explained by another underlying illness or its treatment or 
complications.   
The incidence of methotrexate and leflunomide discontinuation for any reason, with 
any blood-test abnormality, and with any severe blood-test abnormality was highest in 
the first 12-months of shared-care prescribing (Table 2, Figure 1). The cumulative 
annual incidence of discontinuing methotrexate with abnormal, and severely abnormal 
blood-test results was 1 in 24 and 1 in 169 at 1-year, and this reduced to 1 in 45 and 
1 in 352 per-year respectively thereafter. Similarly, for leflunomide, the cumulative 














blood-test results was 1 in 9 and 1 in 106 at 1-year, reducing to 1 in 32 and 1 in 227 
per-year, respectively thereafter. The proportion discontinuing methotrexate with 
abnormal blood test results was lower than that of leflunomide at 1-year and 5-year 
follow-up, being 4.2% (95%CI: 3.7%-4.4%) for methotrexate versus 9.3% (8.1%-
10.7%) for leflunomide at 1 year, and 12.2% (11.5-12.9%) for methotrexate versus 
20.5% (17.8%-23.5%) for leflunomide at 5-year (Figure S3). However, the cumulative 
incidence of methotrexate and leflunomide discontinuation with severe blood-test 
abnormalities were comparable at both time points.  
The incidence of methotrexate discontinuation with raised liver enzymes, and decline 
in kidney function was higher in the first 12-months than subsequently, whereas the 
incidence of methotrexate discontinuation with cytopenia remained stable throughout 
(Table 3, Figure 2, and Figure S4). On the contrary, the incidence of leflunomide 
discontinuation with cytopenia, elevated liver enzymes, and kidney function decline 
was higher in the first 12-months (Table 3, Figure 2). Leflunomide discontinuation with 
severe individual blood-test abnormalities was numerically more common in the first 
12-months than subsequently (Table 3). 
Sensitivity analysis: On excluding people with SLE or CTDs, the incidence (95%CI) of 
methotrexate discontinuation was 27.40 (25.90-28.98)/1,000 person-years for any 
blood-test abnormality and, 5.88 (5.21-6.63)/1,000 person-years for leucopenia, 4.40 
(3.83-5.05)/1,000 person-years for neutropenia and 5.75 (5.09-6.49)/1,000 person-
years for thrombocytopenia. This was comparable to that observed in the entire 
dataset (Table 2). There were no differences when the analyses were stratified for 
duration of follow-up (Data not shown).  
The incidence of methotrexate discontinuation due to elevated liver enzymes was 














the treatment course and for any or severely elevated liver enzymes. However, the 
incidence of methotrexate discontinuation due to cytopenia or renal function decline 
was comparable in the two populations (Table S2).   
Dose reduction: 85.3% and 30% participants in the methotrexate and leflunomide 
cohorts had at least one dose data missing, and their follow-up was censored at this 
time point. Methotrexate dose was reduced more often with abnormal blood-test 
results than leflunomide after the first 12 months (Table 4). However, the cumulative 
incidence of dose-reduction with any blood test abnormality and with severe blood-
test abnormalities were comparable for methotrexate and leflunomide at 1 and 5 years. 
(Figure S3). On evaluating individual blood-test abnormalities, leflunomide dose was 
more likely to be reduced with neutropenia than methotrexate, and less likely to be 
reduced with abnormal LFTs (Table 4). 
Seven participants prescribed methotrexate had dose reduction for severely abnormal 
blood-test results with incidence of 1.03 (0.49-2.16) per 1,000 person-years. Fewer 
than five participants prescribed leflunomide had dose reduction for severely abnormal 
blood-test results during shared care prescribing. Due to office for national statistics 
and CPRD policy to avoid accidental identification, we are unable to present incidence 















Discussion This is the largest study to examine the incidence of treatment changes 
with abnormal blood-test results during long-term methotrexate or leflunomide 
therapy. In comparison, the largest systematic review (SR) of low-dose methotrexate 
included data on liver and bone-marrow toxicity from 3,806 and 3,463 participants from 
29 studies, and the previous largest study of leflunomide included data for 3,325 
participants (9, 20).  
This study focussed on patients successfully initiated on long-term DMARDs as there 
is lack of data on benefit from monitoring during this period (6). It reports that treatment 
changes with abnormal blood-test results are common in the first 12-months after 
hospital-supervised treatment initiation and stabilization, and becomes less frequent 
thereafter. Treatment changes with severe blood-test abnormalities were uncommon 
and became less frequent over time .  
Our observation that 3.3% participants discontinued low-dose methotrexate with 
elevated liver enzymes are comparable to the 3.7% incidence reported in the SR (9), 
and, are higher than those in the CORRONA registry (21). In our study, 2.8% 
participants discontinued methotrexate with cytopenia. This is lower than the 6.7% 
cumulative incidence of cytopenia during methotrexate therapy in the SR (9). The 
incidence of methotrexate discontinuation with leucopenia (0.6% vs 1.2%) and 
neutropenia (0.5% vs. 1.8%) at 1-year was lower than the cumulative incidence 
reported in a recent SR of clinical trials that included events from the treatment 
initiation phase (22). This may be due to the fact that our outcome definition required 
drug discontinuation with cytopenia, whereas the SRs reported on the incidence of 
any cytopenia, including those not requiring treatment discontinuation (9, 22).  
Solomon et al reported a lower cumulative incidence of elevated liver enzymes 














low-dose methotrexate for preventing cardiovascular events in a population without 
AIRD (23). The lower incidence may be due to non-prescription of other DMARDs and 
less NSAID use (23).  
As reported previously, raised liver enzymes were the commonest abnormality 
associated with methotrexate discontinuation, and the risk reduced after 12-months 
(9, 10, 23-25). On the contrary, the incidence of methotrexate discontinuation with 
cytopenia was similar throughout the treatment period. Previous 2-year trials of 
methotrexate have reported cytopenia only occasionally, and unrelated to treatment 
duration (10, 24).  
The cumulative incidence of leflunomide discontinuation with elevated liver enzymes 
(3.0% vs. 3.1%), and with either cytopenia or elevated liver enzymes (7.7% vs. 7.0%) 
were comparable to previous reports (20, 21). As reported previously, there was a 
higher incidence of leflunomide discontinuation with blood-test abnormalities in the 
first 12-months (10).  
Leflunomide was more likely to be discontinued with abnormal blood-tests than 
methotrexate. These findings are contrary to the results of a trial in which folate 
supplementation was not mandatory for participants randomised to methotrexate(10). 
However, in another trial where folate supplementation was mandatory for participants 
randomised to methotrexate there were more leflunomide than methotrexate 
discontinuations for elevated liver enzymes (7.7% vs 4.4%) (26). Folic acid 
supplementation was recommended in the BSR guidelines and became common 
practice in the early 2000s, and our findings of greater liver toxicity with leflunomide 
are expected.  
Methotrexate and leflunomide discontinuation with kidney function decline was 














these drugs may be nephrotoxic. However, published data suggests that 
nephrotoxicity is uncommon with these drugs. Only one case of reversible kidney 
failure due to methotrexate was reported in a clinical trial, and there is one case-report 
of leflunomide induced interstitial nephritis but this was associated with chronic over-
dosing and with no cases of leflunomide nephrotoxicity reported in clinical trials (10, 
26-29). The largest clinical trial to examine the side-effects from low-dose 
methotrexate albeit in a non-AIRD population reported an average 1.9 mL/min/1.73 
m2 improvement in estimated glomerular filtration rate, and 15% lower risk of renal 
adverse events compared to placebo (23). A previous 2-year clinical trial reported no 
change in creatinine with leflunomide, and only a marginal increase in creatinine with 
methotrexate (10). These findings suggest that there is low risk of nephrotoxicity with 
leflunomide and low-dose methotrexate. 
Methotrexate was twice as likely to be discontinued with elevated liver enzymes in 
psoriatic arthritis than in RA, as reported previously (12, 13). However, the rates of 
methotrexate discontinuation due to cytopenia and renal function decline were 
comparable suggesting this risk is target-organ specific. Further research is required 
to understand the underlying mechanism. However, these findings suggest that 
psoriatic arthritis patients treated with methotrexate should be monitored carefully for 
hepatotoxicity and advised to minimise risk factors for the latter.  
Most treatment discontinuations in this study were not due to abnormal blood-test 
results. The cumulative incidence of all-cause methotrexate and leflunomide 
discontinuation at 1-year and 5-year in this study were comparable to previous reports 
(30-32). Given a wide methotrexate dosing range, dose reduction was more common 














Strengths of this study include large sample size allowing us to provide precise 
estimates for anticipated low event rates. Additionally, this study used real-world data, 
thus increasing generalisability. Outcomes were stratified according to their severity 
and time-course to add granularity to the results and increase clinical utility. Data from 
the period when methotrexate or leflunomide was commenced were excluded by 
design and the results are applicable to long-term maintenance treatment where the 
greatest burden of testing lies. Although this may be viewed as a limitation, it does not 
reduce the validity of our findings. Missing outcome data is a concern with studies 
using consultation-based databases. However, the cumulative estimates of drug 
discontinuation reported in this study are consistent with those from previous trials and 
observational studies. Additionally, our validation exercise revealed that only 5% 
outcomes were potentially related to another condition, its complication or its 
treatment. We used a parsimonious list of conditions in this exercise including those 
for which there was only a remote possibility of abnormal blood-test results.  
However, this study has several limitations. Firstly, our findings are not applicable to 
patients at very high risk of drug toxicity and not transferred to shared-care prescribing 
e.g. CKD-4, pre-existing chronic liver disease. However, it is extremely uncommon to 
offer methotrexate or leflunomide to such patients, and the results of our study will 
therefore apply to the vast majority of AIRD patients. Secondly, dose data were 
missing for the majority of methotrexate and a large proportion of leflunomide 
prescriptions. This limits the validity of dose-reduction analysis. Thirdly, CKD 
progression and a serum creatinine increase of >26 μm/L, the minimum change 
required to consider the presence of AKI, was used to ascertain drug discontinuation 
with kidney function decline (17). The guideline specifies that the increase in creatinine 














to inherent large gaps between blood-tests, potentially resulting in an overestimate of 
the incidence of AKI. Our results therefore represent a worst-case scenario with 
respect to impact on kidney function. Some of the abnormal blood-test results could 
be due to concurrent prescription of other DMARDs e.g. sulfasalazine. This can 
potentially elevate the outcome event rate. However, this is unlikely to play a large part 
as our outcome definition required a prescription gap of at-least 90 days and, it can 
reasonably be expected that in this period most rheumatologists will be able to 
ascertain the actual drug responsible for the blood-test abnormality. Moreover, some 
patients prescribed first-line subcutaneous methotrexate for RA from the hospital 
clinic, and stepping down to GP prescribed and monitored oral methotrexate may 
appear as incident users of methotrexate. However, this is likely to be uncommon as 
most patients with RA in the UK are commenced on oral methotrexate first-line and, if 
commenced on subcutaneous methotrexate first-line may have a contraindication to 
oral therapy. Research suggests that patients prescribed subcutaneous methotrexate 
change to the oral route in <3% instances (33).  Additionally, some treatment 
discontinuations in people with SLE may be due to increased disease activity e.g. 
cytopenia resulting in treatment escalation. However, a sensitivity analysis excluding 
cases with SLE or CTD reported similar event rates as the main analysis. Finally, it is 
difficult to attribute causality for adverse events and some potential adverse events 
may be unrelated to the treatment. 
. Methotrexate and leflunomide are uncommonly discontinued for blood-test 
abnormalities after the first year of shared-care prescription and discontinuations for 
severely abnormal blood-test results are even less frequent. These data will be useful 
when counselling patients in routine clinical practice. Elevated liver enzymes were the 














underlines the need to advise patients treated with DMARDs to minimise other risk-
factors for hepatotoxicity. Further research is required to identify risk-factors of target-
organ damage, and, to develop a prognostic model for risk-stratified blood-test 
monitoring. This is being evaluated by our team in another ongoing study that will also 
assess the acceptability and cost-effectiveness of risk-based monitoring. 
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Table 1: Baseline characteristics of participants in the methotrexate (n= 15,670) and 
leflunomide (n=2,689) cohorts.  
 Methotrexate Leflunomide  
Age at cohort entry; mean (SD) 57.2 (14.8) 57 (13.4) 
Female, n (%) 10,115 (64.6) 1,807 (67.3) 
Smoking status    
Non-smoker, n (%)  7,339 (46.8) 1,221 (45.5) 














Ex-smoker, n (%) 4,972 (31.7) 902 (33.6) 
Missing, n (%)  59 (0.4) 8 (0.3) 
Alcohol use    
Non-user, n (%) 3,132 (20) 606 (22.6) 
Low, n (%)  8,714 (55.6) 1,452 (54.1) 
Medium, n (%) 573 (3.7) 80 (3.0) 
Hazardous, n (%)  875 (5.6) 140 (5.2) 
EX-user, n (%) 563 (3.6) 149 (5.6) 
Missing, n (%)  1,813 (11.6) 259 (9.6) 
AIRD type    
RA, n (%) 10,306 (65.8) 1,715 (63.9) 
Lupus/other CTD, n (%) 468 (3.0) 26 (1.0) 
PMR/GCA, n (%) 1,597 (10.2) 203 (7.6) 
Spondyloarthropathy, n (%) 3,299 (21.1) 742 (27.6) 
Other DMARDs   
Leflunomide, n (%) 331 (2.1) -/- 
Methotrexate, n (%) -/- 57 (2.1) 
Sulfasalazine, n (%) 2,660 (17.0) 395 (14.7) 
RA=Rheumatoid arthritis; CTD=Connective tissue disease; PMR=polymyalgia rheumatic; GCA=Giant cell arteritis; 















Table 2: The incidence of methotrexate and leflunomide discontinuation 











Event rate (95%CI)/ 
1000 person-time 
Any reason  
   
   
Ever 3,584 46,571 76.96 (74.48-79.52) 946 4,558 207.54 (194.73-221.20) 
First 12 months 2,185 12,327 177.25 (169.97-184.84) 765 1,593 480.10 (447.26-515.36) 
After12 months 1,399 34,244 40.85 (38.81-43.00) 181 2,965 61.05 (53.01-70.30) 
With any blood-test abnormality             
Ever 1,262 45,435 27.78 (26.29-29.35) 259 4,449 58.22 (51.55-65.76) 
First 12 months 517 12,239 42.24 (38.75-46.05) 168 1,577 106.53 (91.58-123.92) 
After 12 months 745 33,196 22.44 (20.90-24.09) 91 2,872 31.69 (25.89-38.79) 
With severe blood-test abnormality             
Ever 170 46,466 3.66 (3.15-4.25) 28 4,548 6.16 (4.25-8.92) 
First 12 months 73 12,317 5.93 (4.71-7.45) 15 1,592 9.42 (5.68-15.63) 















Table 3: The incidence of methotrexate and leflunomide discontinuation due to individual blood-test abnormalities 
 Methotrexate  Leflunomide  
Outcome Events (n) Person-time 
(years) 
Event rate (95% CI) 
/1000 person-years 
Events (n) Person-time 
(years) 
Event rate (95%CI)/ 
1000 person-time 
Leucopenia (WBC <3.5x109/L)             
Ever 286 46,425 6.16 (5.49-6.92) 76 4,535 16.76 (13.39-20.98) 
First 12 months 97 12,322 7.87 (6.45-9.61) 55 1,590 34.58 (26.55-45.04) 
After 12 months 189 34,103 5.54 (4.81-6.39) 21 2,945 7.13 (4.66-10.91) 
Severe leucopenia (WBC <2.5x109/L)       
Ever 28 46,555 0.60 (0.42-0.87) 5 4,558 1.10 (0.45-2.64) 
First 12 months 11 12,327 0.89 (0.49-1.61) -/- -/- 1.88 (0.61-5.84) 
After 12 months 17 34,228 0.50 (0.31-0.80) -/- -/- 0.68 (0.17-2.70) 
Neutropenia (Neutrophil <1.6x109/L)             
Ever 216 46,476 4.65 (4.07-5.31) 77 4,528 17.01 (13.60-21.26)) 
First 12 months 70 12,324 5.68 (4.49-7.18) 45 1,589 28.31 (21.14-37.92) 
After 12 months 146 34,152 4.28 (3.63-5.03) 32 2,939 10.89 (7.71-15.37) 
Severe neutropenia (Neutrophil <1.0x109/L)       
Ever 31 46,552 0.67 (0.47-0.95) 5 4,557 1.10 (0.46-2.64) 
First 12 months 8 12,326 0.65 (0.32-1.30) -/- -/- 1.88 (0.61-5.84) 
After 12 months 23 34,226 0.67 (0.45-1.01) -/- -/- 0.67 (0.17-2.70) 
Thrombocytopenia (Platelet <140x109/L)             
Ever 264 46,428 5.69 (5.04-6.42) 59 4,537 13.00 (10.08-16.78) 
First 12 months 66 12,323 5.36 (4.21-6.82) 32 1,591 20.11 (14.22-28.44) 
After 12 months 198 34,105 5.81 (5.05-6.67) 27 2.946 9.17 (6.30-13.34)  
Severe thrombocytopenia (Platelet <100x109/L)       
Ever 14 46,571 0.30 (0.18 -0.51) -/- -/- 0.44 (0.11-1.75) 
First 12 months 6 12,327 0.49 (0.22-1.08) -/- -/- 1.26 (0.31-5.02) 
After 12 months 8 34,244 0.23 (0.12-0.47) 0 2,965 0 
ALT or AST >100 IU/L             
Ever 517 46,209 11.19 (10.26-12.20) 80 4,524 17.68 (14.20-22.02) 
First 12 months 272 12,292 22.13 (19.65-24.92) 60 1,586 37.84 (29.38-48.73) 
After 12 months 245 33,917 7.22 (6.38-8.18) 20 2,938 6.81 (4.40-10.54)  
ALT or AST >200 IU/L       
Ever 83 46,526 1.78 (1.44-2.21) 13 4,549 2.86 (1.66 -4.92) 
First 12 months 48 12,321 3.90 (2.94-5.17) 8 1,592 5.03 (2.51-10.05) 
After 12 months 35 34,205 1.02 (0.73-1.42) 5 2,957 1.69 (0.70-4.06) 
CKD progression/creatinine + >26 μmol/L             
Ever 312 46,081 6.77 (6.06-7.57) 51 4,532 11.25 (8.55-14.81) 
First 12 months 118 12,284 9.61 (8.02-11.51) 30 1,590 18.87 (13.19-26.98) 
After 12 months 194 33,797 5.74 (4.99-6.60) 21 2,942 7.14 (4.66-10.93) 
Creatinine >2 times previous value       
Ever 32 46,534 0.69 (0.49-0.97) 5 4,558 1.10 (0.46-2.64) 
First 12 months 6 12,325 0.49 (0.22-1.08) 0 0 0 
















Table 4: Incidence of Methotrexate and Leflunomide dose reduction 
 Methotrexate  Leflunomide  
Outcome Events (n) Person-time 
(years) 






Event rate (95%CI)/ 
1000 person-time 
Any abnormal blood-test result       
Ever 142 6,679 21.26 (18.04-25.06) 47 3,151 14.92 (11.21-19.85) 
First 12 months 77 2,764 27.86 (22.29-34.84) 31 1,176 26.36 (18.54-37.48) 
After first 12 months 65 3,915 16.60 (13.05-21.13) 16 1975 8.10 (4.97-13.20) 
Leucopenia (WBC <3.5x109/L)       
Ever 36 6,785 5.31 (3.83-7.36) 19 3,185 5.97 (3.80-9.35) 
First 12 months 19 2,779 6.84 (4.36-10.72) 14 1,181 11.85 (7.02-20.02) 
After first 12 months 
17 4,006 4.24 (2.64-6.82) 5 2004 2.50 (1.04-5.99) 
Neutropenia (Neutrophil <1.6x109/L)       
Ever 21 6,798 3.09 (2.01-4.74) 23 3,177 7.24 (4.81-10.89) 
First 12 months 14 2,779 5.04 (2.98-8.51) 13 1,182 11.00 (6.39-18.94) 
After first 12 months 7 4,019 4.24 (2.64-6.82) 10 1995 5.04 (2.71-9.35) 
Thrombocytopenia (Platelet <140x109/L)       
Ever 26 6,784 3.83 (2.61-5.63) 9 3,200 2.81 (1.46-5.41) 
First 12 months 11 2,782 3.95 (2.19-7.14) 8 1,183 6.77 (3.38-13.53) 
After first 12 months 15 4,002 3.75 (2.26-6.21) -/- -/- 0.50 (0.07-3.52) 
ALT or AST >100 IU/L                            
Ever 56 6,758 8.29 (6.38-10.77) 9 3,197 2.82 (1.46-5.41) 
First 12 months 31 2,776 11.17 (7.85-15.88) 7 1,184 5.91 (2.82-12.40) 
After first 12 months 25 3982 6.28 (4.25-9.28) -/- 2013 1.00 (0.25-3.97) 
CKD progression/creatinine + >26 μmol/L       
Ever 33 6,787 4.86 (3.46-6.84) 6 3,199 1.88 (0.84-4.17) 
First 12 months 19 2,777 6.84 (4.36-10.73) -/- -/- 1.69 (0.42-6.76) 

















Figure 1: Nelson-Aalen cumulative hazard estimates for methotrexate and 
leflunomide discontinuation due to: any reason [A], any abnormal blood-test results 
[b], any severely abnormal blood-test results [c].   
 
Figure 2: Nelson-Aalen cumulative hazard estimates for drug discontinuation due to 
the individual abnormal blood-test results: methotrexate discontinuation due to mild 
abnormal blood-test results [A], severely abnormal blood-test results [C]; leflunomide 
discontinuation due to mild abnormal blood-test results [B], severely abnormal blood-















Figure S1: Study population selection criteria for inclusion in the methotrexate 
cohort. 
Figure S2: Study population selection criteria for inclusion in the leflunomide cohort. 
Figure S3: Cumulative incidence of methotrexate and leflunomide discontinuation 
and dose reduction at 1-year and 5-years. 
Figure S4: Nelson-Aalen cumulative hazard estimates for drug discontinuation due 
to the individual abnormal blood-test results showing number at-risk at each follow-
up year: methotrexate discontinuation due to mild abnormal blood-test results [A], 
severely abnormal blood-test results [C]; leflunomide discontinuation due to mild 
abnormal blood-test results [B], severely abnormal blood-test results [D]. 
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